Entera Bio (ENTX) Stock Analysis & AI Equity Report
Entera Bio (ENTX) overview
Entera Bio (ENTX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.0m and operating profit of USD -11.5m; the year-end share price was 1.94 USD and market capitalisation was USD 89.6m. Entera Bio is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Entera Bio's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Entera Bio
Entera Bio is a clinical-stage biotechnology company developing oral tablet formulations of peptide and protein replacement therapies. Its pipeline includes candidates targeting PTH(1-34), GLP-1/glucagon, and GLP-2, using its N-Tab platform for oral delivery. Its lead candidate, EB613, is an oral teriparatide tablet being developed for osteoporosis.
Generate the Entera Bio report
Entera Bio is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Entera Bio and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Entera Bio
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.